One Million Faces Against Malaria

Quote: Public/private collaboration is central to advance market commitments (AMCs) to fight diseases including diarrhea, malaria, TB and HIV/AIDS. The goal is to create a market for vaccines that developed-world pharmaceutical firms overlook, by narrowing the gap between returns from these projects and returns from wealthier markets. Sponsors commit in advance of product development to finance vaccine purchases at a set price; in exchange, pharmaceutical companies provide long-term binding supply commitments. Research suggests that AMCs for vaccines against malaria, tuberculosis and even HIV/AIDS could be highly cost-effective. See Exhibit 20. With a commitment to pay $13-15 per person immunized for the vaccine, an overall immunization campaign could cost just $15-$17 per DALY saved in the case of malaria and HIV/AIDS, and approximately $30 in the case of tuberculosis. See Exhibit 20. Earlier this year, several governments, along with the Gates Foundation, launched the pilot $1.5 billion AMC against pneumococcal disease, the leading killer of children worldwide.